Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment (RHUMAJICOVID)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04407923 |
Recruitment Status : Unknown
Verified May 2020 by University Hospital, Brest.
Recruitment status was: Recruiting
First Posted : May 29, 2020
Last Update Posted : May 29, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Juvenile Idiopathic Arthritis COVID 19 Treatment |
Study Type : | Observational |
Estimated Enrollment : | 150 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context |
Actual Study Start Date : | May 25, 2020 |
Estimated Primary Completion Date : | November 25, 2020 |
Estimated Study Completion Date : | November 25, 2020 |

- Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis [ Time Frame: 1 Day ]Reduction or discontinuation of treatment with sDMARD, bDMARD or tsDMARD

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 17 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Juvenile Idiopathic Arthritis satisfying Edmonton criteria
- Ongoing DMARD therapy or AINS for 3 months
Exclusion Criteria:
- Inhability to consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04407923
Contact: Valerie DEVAUCHELLE | 02 98 34 72 64 | valerie.devauchelle-pensec@chu-brest.fr | |
Contact: Valerie DEVAUCHELLE | valerie.devauchelle-pensec@chu-brest.fr |
France | |
CH de Belfort | Not yet recruiting |
Belfort, France, 90015 | |
Contact: Anne Lohse | |
CHU de Bordeaux | Not yet recruiting |
Bordeaux, France, 33000 | |
Contact: Pascal Pillet | |
CHRU de Brest | Recruiting |
Brest, France, 29609 | |
Contact: Valerie Devauchelle-Pensec valerie.devauchelle-pensec@chu-brest.fr | |
AP-HP Hôpital Kremlin-Bicêtre | Not yet recruiting |
Le Kremlin-Bicêtre, France, 94275 | |
Contact: Linda Rossi | |
CHU de Poitiers | Not yet recruiting |
Poitiers, France, 86021 | |
Contact: Elisabeth Gervais | |
CHU de Rennes | Not yet recruiting |
Rennes, France, 35000 | |
Contact: Véronique Despert | |
CHU de Strasbourg | Not yet recruiting |
Strasbourg, France, 67200 | |
Contact: Christelle Sordet | |
CHU de Nancy | Not yet recruiting |
Vandœuvre les Nancy, France, 54711 | |
Contact: Irène Lemelle |
Responsible Party: | University Hospital, Brest |
ClinicalTrials.gov Identifier: | NCT04407923 |
Other Study ID Numbers: |
RHUMAJICOVID (29BRC20.0148) |
First Posted: | May 29, 2020 Key Record Dates |
Last Update Posted: | May 29, 2020 |
Last Verified: | May 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Supporting Materials: |
Study Protocol |
Time Frame: | Data will be available beginning six months and ending five years following the end study |
Access Criteria: | Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
COVID-19 Arthritis Arthritis, Juvenile Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases Coronavirus Infections Coronaviridae Infections |
Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases |